SEC Form 4

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

0									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Instruction 1(b)		File	ed pursuant to Section 16(a) of the Securities Exchange Act of 193	hours per resp	oonse:	0.5		
			or Section 30(h) of the Investment Company Act of 1940					
1. Name and Addro Rubin Eyal	ess of Reporting I	Person*	2. Issuer Name and Ticker or Trading Symbol Protalix BioTherapeutics, Inc. [PLX]		all applicabl Director Officer (giv	10% Own give title Other (spe		ner
		(Middle) APEUTICS, INC. CE PARK, POB 455	3. Date of Earliest Transaction (Month/Day/Year) 08/11/2020		below) Sı	r. VP and CI	below) FO	
(Street) CARMIEL	L3	2161401	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indivi Line) X	Form filed	by One Repo	(Check Applica rting Person One Reporting	
(City)	(State)	(Zip)						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)		4. Securities Disposed Of (5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150.4)
Common Stock	08/11/2020		A		246,146	A	(1)	246,146	Ι	By Trust ⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)	(Instr.	of Deriv Secu Acqu (A) of Dispo of (D) (Instr	of Expira Derivative Securities Acquired (A) or Disposed		Expiration Date (Month/Day/Year)		e and int of rities rlying ative ative (Instr. 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended June 7, 2020 (the "Plan"). Of the shares, 27,855 shares vest on September 22, 2020. The remaining 218,291 of the shares vest. Notwithstanding the foregoing and subject to certain exceptions, the vesting period will accelerate immediately upon a Change in Control, as defined in the Plan.

2. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.

/s/ Joseph R. Magnas, POA 08/13/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.